Repression of Human Reduced Folate Carrier Gene Expression by Wild Type p53*

Bee Ching DingDagger , Johnathan R. WhetstineDagger , Teah L. Witt§, John D. Schuetz, and Larry H. MatherlyDagger §||

From the Dagger  Department of Pharmacology and the § Experimental and Clinical Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201 and  the Department of Pharmaceutical Science, St. Jude Children's Research Hospital, Memphis, Tennessee 38101

Received for publication, June 16, 2000, and in revised form, November 30, 2000


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

The relationship between loss of functional p53 and human reduced folate carrier (hRFC) levels and function was examined in REH lymphoblastic leukemia cells, which express wild type p53, and in p53-null K562 cells (K562pTet-on/p53) engineered to express wild type p53 under control of a tetracycline-inducible promoter. Activation of p53 in REH cells by treatment with daunorubicin was accompanied by decreased (~5-fold) levels of hRFC transcripts and methotrexate transport. Treatment of K562pTet-on/p53 cells with doxycycline resulted in a dose-dependent expression of p53 protein and transcripts, increased p21 protein, decreased dihydrofolate reductase, and G1 arrest with decreased numbers of cells in S-phase. p53 induction was accompanied by up to 3-fold decreases in hRFC transcripts transcribed from the upstream hRFC-B promoter and similar losses of hRFC protein and methotrexate uptake capacity. Expression of p15 in an analogous inducible system in K562 cells resulted in a nearly identical decrease of S-phase cells and dihydrofolate reductase without effects on hRFC levels or activity. When the hRFC-B promoter was expressed as full-length and basal promoter-luciferase reporter constructs in K562pTet-on/p53 cells, induction of p53 with doxycycline resulted in a 3-fold loss of promoter activity, which was reversed by cotransfection with a trans-dominant-negative p53. These studies show that wild type p53 acts as a repressor of hRFC gene expression, via a mechanism that is independent of its effects on cell cycle progression.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

p53 is a 53-kDa nuclear phosphoprotein involved in control of cell growth and apoptosis. Inactivation of the p53 tumor suppressor gene, either by mutation or deletion, has frequently been found in a variety of human malignancies (1-3). Loss of p53 function leads to increased cell proliferation and genetic instability, and reduced capacity for apoptosis (1-3). A major function of p53 is to transcriptionally regulate downstream effector genes (1-3). p53 has been reported to transactivate genes involved in cell proliferation or apoptosis such as Gadd45 (4), MDM2 (5), p21waf1 (6), Bcl2 (7), Bax (8), IGF-BP3 (9), and cyclin G (10). Transcriptional activation is mediated by p53 binding to a consensus site consisting of two copies of a 10-bp1 binding sequence (5'-PuPuPuC(A/T)(T/A)GPyPyPy), separated by up to 13 bp (11, 12). p53 has also been reported to repress transcription of a number of genes, including genes encoding proteins involved in the response of chemotherapeutic drugs such as topoisomerase IIalpha (13, 14), P-glycoprotein (MDR1 (15, 16)), MRP (17), and thymidylate synthase (18). Transcriptional repression by p53 is likely due to protein·protein interactions with transcription factors such as TATA-binding protein (19), Sp1 (20), and CCAAT-binding factor (21). In other cases, p53 repression has been mapped to a p53-negative response element (14). Most recently, histone deacetylases were implicated in transcriptional silencing of the p53 target genes, MAP4 (22) and stathmin (23), through the formation of "repression complexes" composed of the Sin3a corepressor, histone deacetylases, and p53. However, the extent to which these mechanisms of transcriptional repression by p53 can be generalized is unclear.

Although one of the major roles of p53 is to stimulate apoptosis, the relationships between wild type p53 and sensitivity to chemotherapeutic drugs are frequently complex and contradictory. A number of studies suggest that loss of wild type p53 function leads to resistance to chemotherapy and radiation therapy due to decreased susceptibility to apoptosis (24), however, this has not always been found to be the case. For example, loss of wild type p53 has been reported to sensitize mammalian cells to taxol (25) and cisplatin (26). Furthermore, the anti-purine inhibitor, AG2034, was selectively cytotoxic toward cells with nonfunctional p53 that were lacking a functional G1 checkpoint (27). In H35 rat hepatoma cells expressing a trans-dominant-negative p53, levels of P-glycoprotein and mdr1a transcripts were markedly elevated, resulting in resistance to P-glycoprotein substrates (16). Mtx sensitivity was reported to be increased in H35 cells characterized by loss of wild type p53 function (16). However, the basis for this finding was not considered further.

Mtx and related antifolates (Tomudex, 5,10-dideaza-5,6,7,8-tetrahydrofolate) are transported into cells by the RFC (28, 29). For Mtx, RFC-mediated transport is a key element in antitumor activity, reflecting its role in generating intracellular unbound Mtx for complete inhibition of DHFR and for Mtx polyglutamate synthesis (28, 29). Given our interest in the mechanisms of transcriptional control of RFC, we began a systematic investigation to explore the possibility that wild type p53 may regulate RFC. Accordingly, we expressed wild type p53 in p53-null K562 cells under control of a tetracycline-inducible promoter. As described herein, in this system, wild type p53 acts as a potent repressor of hRFC gene expression, via a mechanism that seems to be independent of its well-established effects on cell cycle progression. Rather, decreased hRFC levels and function upon p53 induction are likely due to an inactivation of transcription from the upstream hRFC-B promoter (30-32). We also show that induction of endogenous wild type p53 in REH leukemia cells is accompanied by a dramatic decrease in hRFC expression and Mtx transport.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Chemicals and Reagents-- [alpha -32P]dCTP (3000 Ci/mmol) was purchased from PerkinElmer Life Sciences. [3',5',7-3H]Mtx (20 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA). Unlabeled Mtx was provided by the Drug Development Branch, National Cancer Institute, Bethesda, MD. Both labeled and unlabeled Mtx were purified by high pressure liquid chromatography prior to use (33). Restriction enzymes were purchased from Promega (Madison, WI). Synthetic oligonucleotides were obtained from Genosys Biotechnologies, Inc. (The Woodlands, TX).

Wild type human p53 cDNA (34) was obtained from Dr. Bert Vogelstein (The Johns Hopkins University School of Medicine, Baltimore, MD), and the p15 cDNA (35) was obtained from Dr. David Beach (Cold Spring Harbor Laboratories, Cold Spring Harbor, NY). The TDN-p53 construct was described previously (16). The p53-responsive reporter construct, p53CON, containing the p53 consensus binding sequence (36), was obtained from Dr. Jerry Shay (The University of Texas Southwestern Medical Center, Dallas, TX). Antiserum to purified recombinant DHFR (provided by Dr. R. Blakley, Memphis, TN) was prepared in rabbits by the Pocono Rabbit Farm and Laboratory (Canadensis, PA).

Cell Culture-- K562 human erythroleukemia cells and REH B-lymphoblastic leukemia cells were purchased from the American Type Culture Collection (Rockville, MD). K562 and REH cells were grown in RPMI 1640 medium (Sigma Chemical Co.) containing 10% heat-inactivated iron-supplemented calf serum (Hyclone), 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. Cells were cultured in a 37 °C humidified atmosphere containing 5% CO2/95% air. For cytotoxicity determinations, cells were cultured in complete RPMI 1640 medium containing 10% dialyzed fetal bovine serum. Cell numbers were determined after equivalent numbers of doublings by direct microscopic counting with a hemacytometer.

Expression of an Inducible p53 Construct in K562 Cells-- A commercial "Tet-on" (CLONTECH) kit was used to express wild type p53 in p53-null K562 cells under control of a tetracycline/Dox-inducible promoter (37). The K562pTet-on cell line was developed from wild type K562 cells by transfection with the regulator pTet-on plasmid (5 µg) using Lipofectin (Life Technologies, Inc.), as instructed by the manufacturer. Colonies were isolated in soft agar in the presence of 1 mg/ml G418 (38). G418-resistant clones were expanded and screened by transient transfection with a pTRE-luc reporter plasmid. For reporter gene assays, cells were transfected with a 2.5 µg of pTRE-luc plasmid and treated with and without Dox (2 µg/ml) for 24 h, followed by additional incubation for 48 h. The cell lysates were prepared and tested for luciferase activity, as described below.

To construct the pTRE/p53 plasmid, wild type p53 was cloned into a pTRE response plasmid at the BamHI site. The plasmid was then cotransfected into the K562pTet-on cell line with the pcDNA3.1/Zeo plasmid (0.25 µg, Invitrogen). Colonies were isolated in soft agar, expanded in the presence of 1 mg/ml G418 and 150 µg/ml zeocin, and tested for p53 expression in the presence and absence of Dox (2 µg/ml) by Western blotting, as described below. A "double-stable" resistant clone (designated K562pTet-on/p53), which exhibited no background and a high level of Dox-induced p53 expression, was identified and used for further analysis. K562 pTRE "vector control" cells were generated by transfecting K562pTet-on cells with an empty pTRE vector. An analogous p15 "Tet-on"-inducible cell line (K562p15Tet-on-8) was prepared by transfecting p15- and p16-null K562pTet-on cells with a pTRE/p15 plasmid construct.2

Western Blot Analysis of p53, p21, DHFR, and hRFC-- Soluble protein extracts were prepared by sonication in hypotonic buffer (10 mM Tris-Cl, pH 7.0) containing 1% SDS and proteolytic inhibitors and subjected to SDS-PAGE (39). p53, p21, and DHFR proteins were electrophoretically transferred to PVDF membranes (DuPont (40)) and immunoblotted with anti-p53 monoclonal (DO-1) antibody (Oncogene Research Products), p21waf1 antibody (Oncogene Research Products), and antiserum to purified recombinant human DHFR, respectively. Immunoreactive proteins were visualized by enhanced chemiluminescence (Pierce, Rockford, IL).

For hRFC protein expression, sucrose-gradient-purified plasma membranes were prepared as previously described (41-43). Membrane proteins were solubilized in 10 mM Tris-Cl (pH 7.0) hypotonic buffer and 1% SDS in the presence of proteolytic inhibitors (41-43). Aliquots (100 µg) were subjected to a 7.5% SDS-PAGE and transferred to PVDF membranes followed by immunoblotting. hRFC proteins were detected by chemiluminescence (Lumi Light, Roche Molecular Biochemicals) using protein A-purified glutathione S-transferase-hRFC antibody (43). All antibody incubations were performed in Tween 20/Tris-buffered saline that was supplemented with 0.5% nonfat milk. Light emission was recorded on x-ray film with various exposure times, and the signal was quantitated on a Kodak Digital Science 440CF Image Station.

Northern Analysis-- Total RNAs were isolated from cells with TRIzol reagent (Life Technologies, Inc.). Equal amounts (20 µg) of total RNAs were loaded onto a 0.7% formaldehyde/agarose gel and transferred to nylon membranes (GeneScreen, PerkinElmer Life Sciences), followed by baking the membranes at 80 °C until dry. The 32P-labeled probes (i.e. hRFC, p53, and p15) were prepared by random-priming (Roche Molecular Biochemicals) using [alpha -32P]dCTP, and blots were autoradiographed after hybridization. Densitometry of autoradiographs on x-ray films was performed on the Kodak Digital Science 440CF Image Station. Equal loading of the RNAs was established by ethidium bromide staining of 28 S and 18 S RNAs or by probing with 32P-labeled GAPDH cDNA.

Membrane Transport Methodology-- Exponentially growing cells were treated with Dox over a range of concentrations. After 48 h of incubation, ~1 × 107 cells were harvested for [3H]Mtx (0.5 µM) transport assays (41, 43, 44). Cells were washed twice with D-PBS and resuspended in 2 ml of Hanks' balanced salts. Cells were incubated with [3H]Mtx at 37 °C for 180 s. The reactions were quenched with ice-cold D-PBS, and the cells were washed three times with D-PBS. The cell pellets were dissolved in 1 ml of 0.5 N NaOH. The levels of intracellular radioactivity were expressed in units of pmol/mg of protein, calculated from direct measurements of radioactivity and protein contents of the cell homogenates as determined by the method of Lowry et al. (45).

Transient Transfections of hRFC Promoter-luciferase Reporter Gene Constructs-- The full-length hRFC-B (previously, Pro43; positions -2016 to -959) and the basal hRFC-B (positions -1088 to -960; numbering based on nonintron sequence relative to ATG translation start site) constructs were subcloned into pGL3-Basic plasmid (Promega) as previously described (30, 32). K562pTet-on/p53 cells (~2.5 × 106 cells per 6-well dish) were transfected with 5 µg of hRFC-B luciferase fusion gene constructs in pGL3-Basic, p53CON (5'-GGACATGCCCGGGCATGTCC-3' (36)), or empty pGL3-Basic, along with 25 ng of pRL-SV40, using Lipofectin. Lipofection treatments were for 24 h, followed by Dox induction and an additional incubation for 48 h in complete RPMI 1640 media containing 20% iron-supplemented calf serum. Cell lysates were assayed with a Dual-Luciferase reporter assay system (Promega) on a TD-2420 luminometer (Turner Designs), according to the manufacturer's protocol. The relative luciferase activity was obtained by normalizing to Renilla luciferase activity expressed from the pRL-SV40 construct. For certain experiments, cells were cotransfected with 2.5 µg of a TDN-p53 construct (16).

Flow Cytometry Analysis-- Approximately 1-2 × 106 of K562pTet-on/p53, K562p15Tet-on-8, or pTRE vector cells were harvested after treatment with and without Dox (2 µg/ml) for 48 h, washed twice with D-PBS, and fixed in 70% ethanol. For DNA fluorescence staining, cells were stained in propidium iodide by the method of Crissman and Steinkamp (46) and analyzed by flow cytometry (Becton Dickinson FACScan). Apoptosis was assayed by annexin V staining and flow cytometry using a commercial kit (R&D Systems).

RT-PCR of the hRFC 5'-UTRs-- Total RNAs were isolated from K562pTet-on/p53 cells, treated with and without Dox, and used for the synthesis of cDNA (PerkinElmer Life Sciences RT-PCR kits). cDNAs were amplified with Taq polymerase (Promega) in the presence of GC-Rich reagent (Roche Molecular Biochemicals) and specific 5'-UTR primers and compatible coding sequence primers. Primer pairs for hRFC 5'-UTR were based on the DNA sequence for the 5'-untranslated exons (30, 44) and the hRFC cDNA sequence (Ref. 44; GenBankTM accession number U19720) and are as follows (listed as sense, antisense): KS6 (5'-cggggccctggggtgagt-3', 5'-gccatggtgacgctgtagaa-3'); KS32-1 (5'-tctggaggaaagcgtggat-3', 5'-tgaagccgtagaagcaaaggta-3'); KS32-2 (5'-gcaatcccgaggcgtctcag-3', 5'-ccagcagcggccaggtaggagta-3'); KS32-3 (5'-ctgtccatcggaaactcctgtc-3', 5'-gccatggtgacgctgtagaa-3'); and KS43 (5'-cgagtcgcaggcacagtgtcac-3', 5'-ccagcacggccaggtaggagta-3'). Three separate KS32 primers (designated KS32-1, -2, and -3) were employed to identify the different putative KS32 splice forms, as previously described (30). A 194-bp fragment of the hRFC open reading frame (positions -46 to 148) was amplified as a measure of relative hRFC expression (RFC/P8, 5'-cagtgtcaccttcgtcccctccg-3'; and RFC/JW, 5'-gggtgatgaagctctcccctgg-3'). beta -Actin was amplified with commercial primers (CLONTECH) as an additional control. For all primer sets, PCR conditions were: 1 cycle (95 °C for 4 min) and 32 cycles (95 °C for 30 s, 67 °C for 30 s, 72 °C for 45 s). In separate control experiments, all primer sets were found to amplify from purified cDNA templates with similar efficiencies (not shown).

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Effects of Induction of Endogenous p53 on hRFC Levels in REH Cells-- Loss of functional wild type p53 was originally reported to lead to enhanced Mtx sensitivity in H35 rat hepatoma cells (16). Although this was independent of changes in DHFR in this model (16), it could involve any combination of other determinants of drug response (e.g. Mtx polyglutamylation, Mtx membrane transport by RFC, or levels of thymidylate synthase (28)) and/or secondary effects on cell cycle progression, which manifest as decreased sensitivity to Mtx.

To further explore the relationship between induction of endogenous p53 and hRFC, we used the REH B-lymphoblastic leukemia subline, which expresses high levels of hRFC transcripts and protein, and wild type p53 (47). REH cells were treated with 0.5 µM daunorubicin to induce p53. p53 levels increased over time and were maximal by 6 h (Fig. 1A). Notably, hRFC transcripts also decreased in a time-dependent fashion (~5-fold by 9 h; Fig. 1B) and were accompanied by a similar loss of [3H]Mtx transport (not shown). However, there were no changes in the levels of transcripts for the housekeeping gene, GAPDH (Fig. 1C), suggesting that the loss of hRFC in REH cells is comparatively specific. These data strongly suggest a suppression of hRFC levels and function by wild type p53.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of induction of endogenous wild type p53 on hRFC levels in REH cells. REH cells were treated with 0.5 µM daunorubicin (DNR) to induce endogenous p53. Soluble protein extracts were prepared, and total RNAs were extracted at the indicated times for Western and Northern blots analysis, respectively. A, expression of p53 protein in REH cells was assayed on Western blots with anti-p53 monoclonal antibody (DO-1). B, levels of hRFC transcripts on Northern blots were probed with 32P-labeled hRFC cDNA. C, equal loading of the RNAs in B was established by probing with 32P-labeled GAPDH cDNA.

Generation and Characterization of Double-stable K562pTet-on/p53 Cells-- To better study the relationships between p53 and hRFC levels and function, we generated a double-stable transfectant (designated K562pTet-on/p53) in p53-null K562 cells, using a commercial Tet-on system (37) to express wild type p53 under control of a tetracycline/doxycycline-inducible promoter. We initially measured the time course induction of p53 expression following exposure to a maximum dose of Dox (2 µg/ml). In the absence of Dox, p53 was undetectable in K562pTet-on/p53 cells on Western (Fig. 2A) or Northern blots (not shown). Following Dox treatment, we found that p53 transcripts and protein were detectable as early as 6 h and that induction by Dox was maximal after 48 h of treatment. The induction of p53 protein was dose-dependent over a wide range of Dox concentrations (0.015-2 µg/ml; Fig. 2A), and p21 expression paralleled the induction of p53 on Western blots (Fig. 2B), indicating that p53 was transcriptionally active.


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 2.   Induction of wild type p53 in K562pTet-on/p53 cells decreases the levels of hRFC transcripts and increases DHFR protein. K562pTet-on/p53 cells were treated with various Dox concentrations (0-2 µg/ml) for 48 h. A, the results of a Western blot analysis of p53 protein with increasing doses of Dox are shown. B, induction of p21 in response to increasing p53 was assayed on Western blots with anti-p21waf antibody. C, total RNAs were subjected to Northern blot analysis and probed with a 32P-labeled hRFC cDNA. The arrow indicates the major 3.1-kb hRFC transcript. D, ethidium bromide staining of 28 S and 18 S RNAs for the blot in C were used to assess equal RNA loading. E, total RNAs from both induced (+Dox) and uninduced (-Dox) vector control cells were subjected to Northern analysis to assess the levels of hRFC transcripts. 28 S and 18 S ribosomal RNAs were stained with ethidium bromide as controls for equal loading. F, soluble proteins (20 µg) from induced (+Dox) and uninduced (-Dox) cells were analyzed on Western blots with anti-DHFR antiserum.

At 2 µg/ml Dox, there was obvious G1 arrest with a 3-fold loss in the number of cells in S-phase (Table I) and an ~30% decrease in growth rate (data not shown), compared with cells without Dox treatment. By annexin V staining and flow cytometry analysis, there was no detectable increase in the numbers of apoptotic cells after 48 h of Dox treatment (not shown), indicating that expression of high levels of p53 in K562pTet-on/p53 cells did not stimulate apoptosis. Collectively, our results establish the tightly regulated nature of p53 expression and downstream pathways in K562pTet-on/p53 cells treated with Dox.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Cell cycle distribution of K562pTet-on/p53 and K562p15pTet-on-8 cells
K562pTet-on/p53 and K562p15pTet-on-8 cells were treated with (+) and without (-) Dox (2 µg/ml) for 48 h. Portions of the cells were stained with propidium iodide and analyzed for DNA contents as described under "Materials and Methods."

In growth inhibition assays, preinduction of p53 (with 2 µg/ml Dox) for 48 h was accompanied by insignificant differences in Mtx sensitivities over uninduced cells (IC50 values of 8.83 ± 1.64 and 7.70 ± 0.70 nM (S.E.; n = 3) with and without Dox, respectively). However, unlike H35 cells (16), DHFR levels were significantly decreased (~3-fold) in K562pTet-on/p53 cells in the presence of p53 (Fig. 2F). This was, presumably, due to downstream effects on DHFR transcription (48).

hRFC Expression and Function in K562pTet-on/p53 Cells following p53 Induction-- The lack of a significant change in Mtx sensitivity despite significantly reduced DHFR (Fig. 2F), initially suggested that decreased levels of this enzyme target must somehow be offset by alterations in drug uptake. To directly explore the possibility that p53 may regulate hRFC, K562pTet-on/p53 cells were treated with a wide range of Dox concentrations (0.015-2 µg/ml). After 48 h of incubation, total RNAs were prepared and probed on Northern blots with 32P-labeled full-length hRFC cDNA. hRFC transcripts decreased accompanying expression of p53 and in a dose-dependent manner with increasing concentrations of Dox (Fig. 2C). At a maximum dose of Dox (2 µg/ml), there was an ~70% loss in hRFC transcripts. Likewise, there was a significant loss of immunoreactive hRFC protein, detected with hRFC-specific antibody on Western blots (Fig. 3). Furthermore, there was a nearly identical dose-dependent decrease in [3H]Mtx influx capacity (Fig. 4A) in K562pTet-on/p53 cells treated with Dox. At 2 µg/ml Dox, hRFC transport activity was only ~30% of the level for the untreated control. By contrast, neither hRFC transcripts (Fig. 2E), hRFC protein (not shown), nor Mtx transport activity (Fig. 4B) significantly differed in pTRE vector control cells in the presence and absence of 2 µg/ml Dox.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 3.   Expression of wild type p53 in K562pTet-on/p53 cells is associated with a loss of hRFC protein. K562pTet-on/p53 cells were treated with 2 µg/ml of Dox for 48 h, and sucrose gradient-purified plasma membranes of Dox-induced cells (+) were prepared in parallel with the uninduced cells (-). Aliquots of membrane proteins (100 µg) were electrophoresed on a 7.5% SDS-PAGE gel, transferred to PVDF membrane, and probed with a protein A-purified hRFC-specific antibody. Enhanced chemiluminescence was used for visualization. The broadly migrating ~85-kDa hRFC protein band (38, 43, 44), detectable with hRFC antiserum, is indicated.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   Influx of [3H]Mtx by hRFC in K562pTet-on/p53 (A) and vector control (B) cells. Following exposure to a wide range of Dox concentrations (0.015-2 µg/ml), cells were harvested and incubated with tritiated Mtx (0.5 µM) for 180 s at 37 °C. Transport activity was expressed in units of pmol/mg of protein as a function of Dox concentration (in µg/ml) and are presented as mean values (±S.E.) from three experiments in duplicate.

Effects of p15 Induction in K562p15Tet-on-8 Cells on S-phase Fraction and hRFC Levels-- hRFC levels and function have been linked to cell proliferation (49). Thus, the changes in hRFC levels and function upon p53 induction (Figs. 2C, 3, and 4A) could potentially be due to indirect effects of elevated p21, resulting in the loss of S-phase fraction (Table I) and S-phase-dependent hRFC expression. In such a case, an identical effect should result from elevated levels of p15, another inhibitor of cyclin-dependent kinases-4 and -6 (34). However, for the analogous p15 Tet-on-inducible model (K562p15Tet-on-8), hRFC mRNAs were unchanged on Northern blots accompanying p15 induction with 2 µg/ml Dox (Fig. 5), even though there was a nearly identical ~3-fold loss of S-phase cells (Table I). Likewise, Mtx transport by hRFC was completely unaffected upon p15 induction (1.23 versus 1.31 pmol/mg of protein with and without Dox pretreatment, after 180-s incubation with 0.5 µM Mtx). Thus, a simple cell cycle arrest does not appear to explain the decreased hRFC levels in cells that up-regulate wild type p53.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of p15 induction in K562p15Tet-on-8 cells on hRFC levels. K562p15Tet-on-8 cells were induced with 2 µg/ml Dox for 48 h followed by total RNA extraction. When these cells were subjected to flow cytometry analysis, a G1 arrest and an ~3-fold loss of S-phase fraction were detected (Table I). A, total RNAs were fractionated on a 0.7% formaldehyde/agarose gel and hybridized with 32P-labeled hRFC cDNA to detect the major 3.1-kb hRFC transcript. B, the blot was then stripped and reprobed with 32P-labeled p15 cDNA to assess the levels of p15 transcripts in the presence (+) and absence (-) of Dox. C, 28 S and 18 S ribosomal RNAs were stained with ethidium bromide as controls for equal loading. D, soluble proteins (20 µg) from induced (+Dox) and uninduced (-Dox) cells were analyzed on Western blots with anti-DHFR antiserum.

It was of interest that DHFR also decreased (~2.5 fold) upon p15 induction in K562p15Tet-on-8 cells (Fig. 5D), yet this was not accompanied by a corresponding increased Mtx sensitivity (6.85 ± 0.15 and 9.00 ± 1.00 nM, in the presence and absence of Dox, respectively). The basis of this paradoxical result is not entirely certain, however, it may relate to additional downstream effects of p15 (and also p53) on other folate-dependent pathways that impact Mtx response. For instance, elevated p15 (and p21) might result in decreased thymidylate synthase (50), analogous to DHFR, however, this would increase Mtx resistance (51). Clearly, changes in levels of p15 or p53 can potentially cause a multiplicity of effects in different cells and tissues, involving hRFC, DHFR, and, possibly, thymidylate synthase, which are not easily reconciled in terms of their Mtx sensitivities.

Effects of p53 Induction in K562pTet-on/p53 Cells on hRFC Transcript Stability-- p53 has been reported to exhibit RNA binding activity (52), which could conceivably affect mRNA stabilities. Accordingly, the loss of hRFC transcripts in K562pTet-on/p53 cells treated with Dox could possibly reflect downstream effects of p53 on hRFC transcript stability. To directly assess this possibility, K562pTet-on/p53 cells were pretreated with Dox (2 µg/ml) for 24 h and subsequently with 10 µg/ml actinomycin D. Changes in hRFC transcript levels were followed over 12 h on Northern blots (data not shown). Under these conditions, the rates of hRFC transcript turnover were identical and independent of p53 induction (half-lives of 5.2 and 5.9 h in the presence and absence of Dox, respectively).

Effects of p53 on hRFC Involve Transcriptional Repression of the Upstream hRFC-B Promoter-- The hRFC gene encodes transcripts characterized by heterogeneous 5'-UTRs, reflecting multiple transcription starts and variable splicing of alternative exons, transcribed from dual TATA-less and CAAT-less promoters (30-32, 44). By 5'-RACE (rapid amplification of cDNA ends) analysis, hRFC transcripts in K562 cells contain predominantly (~93%) the KS43 5'-UTR from exon 1, transcribed from the upstream hRFC-B ("Pro43") promoter (53). When total RNAs from K562pTet-on/p53 cells were reverse-transcribed and PCR-amplified to identify the unique 5'-UTRs (previously designated KS6 and KS43, and the KS32 splice forms I, II, and III (32, 45)), transcripts with the KS43 5'-UTR again predominated (>90%; Fig. 6A). When normalized to beta -actin (Fig. 6C), both the KS43 5'-UTR and open reading frame PCR products were significantly decreased (~70%) in cells treated with Dox (+Dox; panel B) compared with untreated cells (-Dox; panel A). Thus, the loss of hRFC transcripts in K562pTet-on/p53 cells upon p53 induction is completely due to effects on KS43 transcripts transcribed from the hRFC-B promoter.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 6.   RT-PCR analysis of hRFC-B transcripts for 5'-UTR utilization. Total RNAs were extracted from K562pTet-on/p53 cells treated for 48 h with (B) and without (A) Dox and used directly for synthesis of the cDNA. cDNAs were PCR amplified with primer sets specific for the KS6 (lane 1), KS32 (I, II, and III; lanes 2-4, respectively), and KS43 (lane 5) 5'-UTRs (30, 44), and the hRFC open reading frame (lane 6). PCR products were fractionated on a 2% agarose gel and detected with ethidium bromide staining. A 100-bp DNA ladder (M) and the sizes of the major PCR products are indicated. C, a commercial primer set was used to amplify beta -actin (838 bp) to normalize the relative levels of hRFC PCR products in the presence and absence of Dox.

To further examine the mechanism(s) involved with this effect, full-length (positions -2016 to -959) and basal (positions -1088 to -960) hRFC-B promoter constructs (in pGL3-Basic) (32), containing a luciferase reporter gene, were transiently expressed in K562pTet-on/p53 cells in the presence and absence of Dox (2 µg/ml). For both full-length and basal promoter constructs, induction of p53 resulted in an ~3- to 4-fold decrease in relative luciferase activity (Fig. 7, A and B, respectively). p53 repression of the low residual levels of basal activity was completely abolished in a promoter construct in which a highly conserved GC-box element (cccgccc; positions -1081 to -1075 (32)) was mutated (to cccgaac; data not shown). Luciferase activity was completely unaffected by Dox for the vector control cells (not shown). When a TDN-p53 expression construct was cotransfected with the full-length hRFC-B construct, the repressive effects of p53 were largely abolished (Fig. 7A). A similar effect of TDN-p53 on basal hRFC-B activity was also observed (not shown). Fig. 7C shows that induction of p53 results in a potent stimulation of luciferase activity in K562pTet-on/p53 cells transfected with the p53-responsive p53CON reporter plasmid (36).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 7.   Effects of p53 on hRFC levels in K562pTet-on/p53 cells involve transcriptional repression of both full-length and basal hRFC-B promoters. Full-length (A) and basal (B) hRFC-B promoter constructs linked to a luciferase reporter gene in pGL3-Basic, were transiently expressed in K562pTet-on/p53 cells with (+) and without (-) 2 µg/ml Dox. Five micrograms of each hRFC promoter construct was cotransfected with 25 ng of pRL-SV40 plasmid for normalization. Also shown in A are the effects of cotransfections with the TDN-p53 construct (2.5 µg) on luciferase activity of the full-length hRFC-B promoter construct (5 µg). C shows the effects of p53 induction on promoter activity of the p53-responsive luciferase reporter construct, p53CON, as a positive control. All data are presented mean values (±S.E.) from three experiments in duplicate.

These results show that induction of p53 suppresses hRFC-B promoter activity and that this can be reversed with a trans-dominant-negative form of p53. Furthermore, the inhibitory effects of p53 can be localized to the hRFC-B minimal promoter region. The finding that transcriptional repression by p53 can be abolished by mutating the highly conserved GC-box suggests a direct or indirect effect of p53 on Sp1/Sp3 transactivation of the hRFC-B promoter.

Mechanisms of p53 Transcriptional Repression of the Basal hRFC-B Promoter-- The mechanism by which p53 typically regulates cellular functions involves its role as a transcriptional regulatory activator/repressor (1-3) and may involve binding to specific consensus sequences (11, 12, 14) and/or direct binding with individual transcription factors (18-21). Although the p53 effects on hRFC transcription can be localized to the basal hRFC-B promoter, no p53 response element in this region can be identified.

An important role for the Sp1 family of transcription factors in activating basal hRFC-B transcription (via the conserved GC-box) has been established by gel shift analyses of nuclear extracts prepared from HepG2 and HT1080 cells and by transient cotransfections in Drosophila SL2 cells with a pPac-Sp1 expression vector and hRFC-B promoter constructs in pGL3-Basic vector (32). p53 has been reported to bind with Sp1 (20), and its repressive effects on Sp1-regulated promoters (MRP1 (17) and thymidylate synthase (18)) have been suggested to occur by direct association and functional antagonism of promoter transactivation. Consistent with this notion, in Drosophila cells cotransfected with Sp1, p53, and the hRFC-B promoter, a potent suppressive effect on promoter activity by p53 was observed (data not shown).

However, on gel shifts with a 46-bp oligonucleotide (positions -1088 to -1043) encompassing the Sp1 binding site (-1081 to -1075) (32) and nuclear extracts prepared from K562pTet-on/p53 cells, treated with and without Dox (2 µg/ml), there were no notable differences in the levels or migrations of the DNA·Sp1 or DNA·Sp3 complexes (not shown). The DNA·Sp1 and DNA·Sp3 complexes could be supershifted with antibodies specific for Sp1 and Sp3, respectively, however, p53 antibody did not effect a supershift (not shown).

Of course, putative Sp1·p53 interactions may not necessarily be detectable on gel shifts, due to a lack of sensitivity and/or use of suboptimal binding conditions. Alternatively, the repressive effects of p53 on hRFC transcription may include downstream effects on Sp1 or Sp3 levels or structure (e.g. phosphorylation or O-glycosylation (54, 55)) not detectable on gel shifts or effects of p53 on accessory transcription proteins. Indeed, any repressive effect of p53 can best be interpreted within the overall context of hRFC-B promoter structure and function. The nature of the putative inhibitory complex that forms ultimately depends not only on the levels of individual transcription factors but on the formation of the transcription initiation complex, and assorted other elements such as transcription factor accessibility and post-translational modifications (see above), the presence of upstream inhibitory or activating elements, and the overall promoter architecture.

Conclusions-- In summary, our results document a suppression of hRFC levels and function by wild type p53, suggesting that hRFC is an important cellular target for this tumor suppressor. Wild type p53 represses hRFC expression at the level of transcription, and it appears to involve direct or indirect effects on the transactivation of the hRFC-B minimal promoter. The mechanism of p53-mediated transcriptional repression of hRFC and its similarity to the p53 repression of other TATA-less promoters is not well established. However, for hRFC, it seems to be independent of its effects on cell cycle progression.

Although our findings suggest that treatment with DNA-damaging agents (e.g., chemotherapy, irradiation) could possibly attenuate sensitivities to antifolates due to decreased hRFC for cells that express wild type p53, the ramifications of this likely depend on the intracellular enzyme target and may vary in different tumors and tissues. Likewise, decreased uptake of reduced folates by this mechanism may exacerbate the effects of DNA-damaging agents, due to perturbations of nucleotide pools required for DNA repair. Clearly, a better understanding of the regulation of hRFC expression by wild type p53 should provide insights into the chemotherapeutic efficacy of antifolates in combination with other anticancer drugs and into the relationships between nutritional folate deficiency, genetic instability, and malignancy.

    ACKNOWLEDGEMENTS

We thank Drs. Bert Vogelstein, Jerry Shay, and David Beach for providing plasmid constructs for our studies and Dr. Ray Blakley for providing recombinant human DHFR protein for antiserum preparation. The assistance of Dr. Surreyya Savasan with the apoptosis assays is appreciated.

    FOOTNOTES

* This study was supported by Grants CA53535, CA77641, and ES05851 from the National Institutes of Health, and by the American Lebanese Syrian Associated Charities.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Experimental and Clinical Therapeutics Program, Karmanos Cancer Institute, 110 E. Warren Ave., Detroit, MI 48201. Tel.: 313-833-0715 (ext. 2407); Fax: 313-832-7294; E-mail: matherly@kci.wayne.edu.

Published, JBC Papers in Press, December 5, 2000, DOI 10.1074/jbc.M005248200

2 S. Shah, J. Taub, T. L. Witt, J. Pollock, B. C. Ding, M. Amylon, J. Pullen, Y. Ravindranath, and L. H. Matherly, manuscript submitted.

    ABBREVIATIONS

The abbreviations used are: bp, base pair(s); DHFR, dihydrofolate reductase; Dox, doxycycline; D-PBS, Dulbecco's phosphate-buffered solution; RFC, reduced folate carrier; hRFC, human RFC; Mtx, methotrexate; MRP, multidrug resistance protein; PAGE, polyacrylamide gel electrophoresis; PVDF, polyvinylidene difluoride; RACE, rapid amplification of cDNA ends; RT-PCR, reverse transcription-polymerase chain reaction; TDN, trans-dominant-negative; UTR, untranslated region; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

1. Ko, L. J., and Prives, C. (1996) Genes Dev. 10, 1054-1072[CrossRef][Medline] [Order article via Infotrieve]
2. Levine, A. J. (1997) Cell 88, 323-331[Medline] [Order article via Infotrieve]
3. Agarwal, M. L., Taylor, W. R., Chernov, M. V., Chernova, O. B., and Stark, G. R. (1998) J. Biol. Chem. 273, 1-4[Free Full Text]
4. Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. (1992) Cell 71, 587-597[Medline] [Order article via Infotrieve]
5. Barak, Y., Juven, T., Haffner, R., and Oren, M. (1993) EMBO J. 12, 461-468[Abstract]
6. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parson, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) Cell 75, 817-825[Medline] [Order article via Infotrieve]
7. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. (1994) Oncogene 9, 1799-1805[Medline] [Order article via Infotrieve]
8. Miyashita, T., and Reed, J. C. (1995) Cell 80, 293-299[Medline] [Order article via Infotrieve]
9. Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., and Kley, N. (1995) Nature 377, 646-649[CrossRef][Medline] [Order article via Infotrieve]
10. Okamoto, K., and Beach, D. (1994) EMBO J. 13, 4816-4822[Abstract]
11. Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., and Vogelstein, B. (1991) Science 252, 1708-1711[Medline] [Order article via Infotrieve]
12. Zambetti, G. P., Bargonetti, J., Walker, K., Prives, C., and Levine, A. J. (1992) Genes Dev. 6, 1143-1152[Abstract]
13. Sandri, M. I., Isaacs, R. J., Ongkeko, W. M., Harris, A. L., Hickson, I. D., Broggini, M., and Vikhanskaya, F. (1996) Nucleic Acids Res. 24, 4464-4470[Abstract/Free Full Text]
14. Wang, Q., Zambetti, G. P., and Suttle, D. P. (1997) Mol. Cell. Biol. 17, 389-397[Abstract]
15. Chin, K. V., Ueda, K., Pastan, I., and Gottesman, M. M. (1992) Science 255, 459-462[Medline] [Order article via Infotrieve]
16. Thottassery, J. V., Zambetti, G. P., Arimori, K., Schuetz, E. G., and Schuetz, J. D. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11037-11042[Abstract/Free Full Text]
17. Wang, Q., and Beck, W. T. (1998) Cancer Res. 58, 5762-5769[Abstract]
18. Lee, Y., Chen, Y., Chang, L. S., and Johnson, L. F. (1997) Exp. Cell Res. 234, 270-276[CrossRef][Medline] [Order article via Infotrieve]
19. Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J., and Shenk, T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 12028-12032[Abstract]
20. Borellini, F., and Glazer, R. I. (1993) J. Biol. Chem. 268, 7923-7928[Abstract/Free Full Text]
21. Agoff, S. N., Hou, J., Linzer, D. I., and Wu, B. (1993) Science 259, 84-87[Medline] [Order article via Infotrieve]
22. Murphy, M., Ahn, J., Walker, K. K., Hoffman, W. H., Evans, R. M., Levine, A. J., and George, D. L. (1999) Genes Dev. 13, 2490-2501[Abstract/Free Full Text]
23. Ahn, J., Murphy, M., Kratowicz, S., Wang, A., Levine, A. J., and George, D. L. (1999) Oncogene 18, 5954-5958[CrossRef][Medline] [Order article via Infotrieve]
24. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. (1994) Science 266, 807-810[Medline] [Order article via Infotrieve]
25. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y., Foster, S. A., Demers, G. W., and Galloway, D. A. (1996) Nat. Med. 2, 72-79[Medline] [Order article via Infotrieve]
26. Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., and Zunino, F. (1996) Cancer Res. 56, 556-562[Abstract]
27. Zhang, C. C., Boritzki, T. J., and Jackson, R. C. (1998) Cancer Chemother. Pharmacol. 41, 223-228[CrossRef][Medline] [Order article via Infotrieve]
28. Goldman, I. D., and Matherly, L. H. (1985) Pharmacol. Ther. 28, 77-107[CrossRef][Medline] [Order article via Infotrieve]
29. Jansen, G. (1999) in Antifolate Drugs in Cancer Therapy (Jackman, A. L., ed) , pp. 293-321, Humana Press, Inc., Totowa, NJ
30. Zhang, L., Wong, S. C., and Matherly, L. H. (1998) Biochem. J. 332, 773-780[Medline] [Order article via Infotrieve]
31. Tolner, B., Roy, K., and Sirotnak, F. M. (1998) Gene 211, 331-334[CrossRef][Medline] [Order article via Infotrieve]
32. Whetstine, J. R., and Matherly, L. H. (November 14, 2000) J. Biol. Chem. 10.1074/jbc.M008074200
33. Fry, D. W., Yalowich, J. C., and Goldman, I. D. (1982) J. Biol. Chem. 257, 1890-1896[Free Full Text]
34. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., and Vogelstein, B. (1990) Science 249, 912-915[Medline] [Order article via Infotrieve]
35. Hannon, G. J., and Beach, D. (1995) Nature 371, 257-261
36. Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., and Shay, J. W. (1992) Mol. Cell. Biol. 12, 2866-2871[Abstract]
37. Gossen, M., Sabine, F., Bender, G., Muller, G., Hillen, W., and Bujard, H. (1995) Science 268, 1766-1769[Medline] [Order article via Infotrieve]
38. Wong, S. C., McQuade, R., Proefke, S. A., Bhushan, A., and Matherly, L. H. (1997) Biochem. Pharmacol. 53, 199-206[CrossRef][Medline] [Order article via Infotrieve]
39. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
40. Matsudaira, P. (1987) J. Biol. Chem. 262, 10035-10038[Abstract/Free Full Text]
41. Matherly, L. H., Czajkowski, C. A., and Angeles, S. M. (1991) Cancer Res. 51, 3420-3426[Abstract]
42. Matherly, L. H., Angeles, S. M., and Czajkowski, C. A. (1992) J. Biol. Chem. 267, 23253-23260[Abstract/Free Full Text]
43. Wong, S. C., Zhang, L., Witt, T. L., Proefke, S. A., Bhushan, A., and Matherly, L. H. (1999) J. Biol. Chem. 274, 10388-10394[Abstract/Free Full Text]
44. Wong, S. C., Proefke, S. A., Bhushan, A., and Matherly, L. H. (1995) J. Biol. Chem. 270, 17468-17475[Abstract/Free Full Text]
45. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275[Free Full Text]
46. Crissman, H. A., and Steinkamp, J. A. (1973) J. Cell Biol. 59, 766-771[Free Full Text]
47. Zhou, M., Yeager, A. M., Smith, S. D., and Findley, H. W. (1995) Blood 85, 1608-1614[Abstract/Free Full Text]
48. Li, W. W., Fan, J., Hochhauser, D., Banerjee, D., Zielinski, Z., Almansan, A., Yin, Y., Kelly, R., Wahl, G. M., and Bertino, J. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10436-10440[Abstract]
49. Chello, P. L., Sirotnak, F. M., and Dorick, D. M. (1980) Mol. Pharmacol. 18, 274-280[Abstract]
50. Farnham, P. J., Slansky, J. E., and Kollmar, R. (1993) Biochim. Biophys. Acta Rev. Cancer 1155, 125-131[CrossRef][Medline] [Order article via Infotrieve]
51. White, J. C., and Goldman, I. D. (1981) J. Biol. Chem. 256, 5722-5727[Free Full Text]
52. Oberosler, P., Hloch, P., Ramsperger, U., and Stahl, H. (1993) EMBO J. 12, 2389-2396[Abstract]
53. Ding, B. C., Witt, T. L., Hukku, B., Heng, H., Zhang, L., and Matherly, L. H. (2001) Biochem. Pharmacol., in press
54. Black, A. R., Jensen, D., Lin, S. Y., and Azizkhan, J. C. (1999) J. Biol. Chem. 274, 1207-1215[Abstract/Free Full Text]
55. Roos, M., Su, K., Baker, J., and Kudlow, J. (1997) Mol. Cell. Biol. 17, 6472-6480[Abstract]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.